

# **Jyothy Laboratories**

CMP: INR310 TP: INR350 (+13%) Neutral

# Weak performance continues; margins under pressure

- Jyothy Laboratories (JYL) posted flat YoY sales growth in 2QFY26, with volumes rising 3% (est. 4%; 1QFY26 4%). The difference between value and volume growth was primarily due to MRP reductions, higher grammage, and promotional price-offs in select categories. JYL expects a 2%-2.5% value volume gap at the overall level going forward. GT channel continued to remain under pressure, while alternate channels grew double digits.
- Fabric Care grew 6% in value terms, led by liquid detergents, which more than doubled YoY. EBIT margin contracted 300bp YoY to 22%, resulting in a 7% YoY EBIT decline. Dishwash sales declined 4% YoY (volumes +3% YoY), primarily due to MRP reductions and grammage offers on bars. Liquid dishwash outperformed the bars category. EBIT margin contracted 180bp YoY to 17.3%, with EBIT declining 13% YoY.
- The Household Insecticides (HI) business continued to remain weak, marking a 9% YoY decline on a flat base as the category continued to face near-term headwinds. The sales have been on a declining trajectory for four quarters now. EBIT margin stood at -9.7% vs. -9.5% YoY. The Personal Care business sales declined 4%, impacted by GST transition; EBIT margin saw a sharp contraction of 1,090bp YoY to 2.7%, with EBIT declining 81% YoY. JYL expects the segment to return to growth in 2HFY26.
- Gross margin contracted 210bp YoY and flat QoQ to 48.1% (est. 50.3%). Higher employee costs and brand investments led to an EBITDA margin contraction of 280bp YoY, bringing it to 16.1% (below), with EBITDA declining 15% YoY. JYL expects EBITDA margin to be in the range of 16%-17% in 2HFY26.
- We model a CAGR of 8% in revenue/EBITDA over FY25-28E. We have been cautious on revenue growth and sustaining operating margin previously as well. We cut EPS by 2-3% for FY26/FY27. We reiterate our Neutral rating on the stock with a TP of INR350 (premised on 30x Sep'27E P/E).

# Broadly in-line sales; miss on margins

- Volume growth stood at 3%: JYL's net sales were flat YoY at INR7,361m (est. INR7,567m). Volume growth was 3% (est. 4%) in 2QFY26. In Dishwashing, liquids outperformed bars, while in Fabric Care, the liquid detergent range continued to scale rapidly, with revenue more than doubling YoY.
- Contraction in margins: Gross margin contracted 210bp YoY and remained flat QoQ at 48.1% (est. 50.3%). Employee expenses rose 5%, while Ad spends and other expenses rose 1% each. EBITDA margin contracted 280bp YoY to 16.1%. (est. 17.9%).
- Decline in profitability: EBITDA declined 14.6% YoY to INR1,183m (est. of INR1,351m). PBT declined 12.5% YoY to INR1,187m (est. INR1,328m). Adj. PAT declined 16% YoY to INR878m (est. INR1,009m).
- In 1HFY25, revenue grew 1% YoY, while EBITDA/APAT declined 11%.

# TP change Rating change

Bloomberg	JYL IN
Equity Shares (m)	367
M.Cap.(INRb)/(USDb)	113.9 / 1.3
52-Week Range (INR)	504 / 268
1, 6, 12 Rel. Per (%)	-3/-15/-38
12M Avg Val (INR M)	234

### Financials & Valuations (INR b)

Y/E March	2026E	2027E	2028E
Net Sales	29.9	32.3	35.0
Sales Gr. (%)	5.1	8.1	8.4
EBITDA	5.0	5.6	6.2
EBITDA Margins (%)	16.6	17.3	17.6
Adj PAT	3.8	4.3	4.8
Adj. EPS (INR)	10.3	11.7	13.0
EPS Gr. (%)	1.3	13.0	11.1
BV/Sh (INR)	57.2	62.4	68.8
Ratios			
RoE (%)	18.3	19.5	19.8
RoCE (%)	18.3	19.8	20.0
Payout (%)	63.2	56.0	50.4
Valuation			
P/E (x)	30.0	26.5	23.9
P/BV (x)	5.4	5.0	4.5
EV/EBITDA	21.5	18.7	16.4
Div. Yield (%)	1.7	1.7	1.7

### Shareholding Pattern (%)

•		•	
As On	Sep-25	Jun-25	Sep-24
Promoter	62.9	62.9	62.9
DII	16.1	16.0	15.3
FII	12.1	12.7	15.1
Others	8.9	8.5	6.7

FII includes depository receipts



### Highlights from the management commentary

- The operating environment in 2QFY26 was mixed as the quarter started on a positive note. However, the GST rate revision caused trade disruptions in September, leading to flat growth YoY. The early demand signals for 3QFY26 are encouraging. The company expects demand environment to strengthen in 2HFY26.
- General trade continued to remain under pressure. Modern trade, including e commerce and quick commerce, sustained double-digit growth. Fabric care and dishwash performed well in these channels.
- In 2QFY26, JYL made significant investments in Margo, which, along with price hikes taken in December last year and elevated palm oil prices, weighed on personal care EBIT margins. Over the next couple of quarters, EBIT margins are expected to return to double digits.
- The company expects volume growth in double digits by 4QFY26. It also expects 2%-2.5% value volume gap at the overall level going forward.
- EBITDA margin is expected to be in the range of 16-17% in 2HFY26.

### Valuation and view

- We cut our EPS estimates by 2%-3% each for FY26E-28E.
- We believe that while 2HFY26 will be better than 1HFY26 for most FMCG names, elevated competitive intensity could limit JYL's growth in the near term. Market share gains, the success of new launches, a recovery in personal care, and the turnaround of HI portfolio will be crucial for JYL's earnings growth. JYL's margin expansion beyond ~18% is also constrained by its focus on the mass and rural segments. Therefore, we believe its growth potential is adequately priced in at the current valuation. We reiterate our Neutral rating on the stock with a TP of INR350 (premised on 30x Sep'27E P/E).

<b>Consolidated Quarterly Pe</b>	rformance											(INR m)
Y/E March		FY2	25			FY2	6E				FY26E	Var.
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY25	FY26E	2QE	(%)
Volume growth (%)	11%	3%	8%	5%	4%	3%	8%	9%	6%	8%	4%	
Net Sales	7,418	7,338	7,045	6,670	7,512	7,361	7,633	7,406	28,470	29,912	7,567	-2.7
YoY change (%)	8.0	0.2	4.0	1.1	1.3	0.3	8.4	11.0	3.3	5.1	3.1	
Gross Profit	3,805	3,683	3,506	3,281	3,608	3,537	3,862	4,099	14,275	15,106	3,806	-7.1
Margins (%)	51.3	50.2	49.8	49.2	48.0	48.1	50.6	55.3	50.1	50.5	50.3	
EBITDA	1,335	1,385	1,158	1,119	1,242	1,183	1,307	1,232	4,996	4,964	1,351	-12.5
EBITDA growth %	13.7	2.3	-2.4	3.3	-7.0	-14.6	12.9	10.1	4.1	-0.6	-2.4	
Margins (%)	18.0	18.9	16.4	16.8	16.5	16.1	17.1	16.6	17.5	16.6	17.9	
Depreciation	134	139	143	146	147	152	151	150	561	601	149	
Interest	14	14	15	17	13	14	16	19	59	62	15	
Other Income	137	125	139	155	194	170	190	141	556	695	140	
PBT	1,324	1,357	1,138	1,112	1,275	1,187	1,330	1,203	4,931	4,996	1,328	-10.6
Tax	307	307	264	306	307	309	319	264	1,184	1,200	319	
Rate (%)	23.2	22.6	23.2	27.6	24.1	26.1	24.0	21.9	24.0	24.0	24.0	
Adjusted PAT	1,017	1,050	874	806	968	878	1,011	940	3,747	3,796	1,009	-13.0
YoY change (%)	16.6	1.0	-3.9	3.1	-4.8	-16.4	15.7	16.6	4.0	1.3	-3.9	

E: MOFSL Estimates





## Highlights from the management commentary

### Performance and outlook

- The operating environment in 2QFY26 was mixed as the quarter started on a positive note. However, the GST rate revision caused trade disruptions in September, leading to flat growth YoY.
- The early demand signals for 3QFY26 are encouraging. The company expects the demand environment to strengthen in 2HFY26.
- JYL's personal care portfolio, which accounted for ~11% of its 2QFY26 sales, benefited from lower GST rates.
- The difference between value and volume growth was primarily due to MRP reductions, higher grammage, and promotional price offs in select categories.
- By 4QFY26, the volume growth is expected to be in double digits.
- It expects 2-2.5% value volume gap at the overall level going forward.
- General trade continued to remain under pressure. Modern trade, including e commerce and quick commerce, sustained double digit growth. Fabric care and dishwash performed well in these channels.
- The current rural demand trends continues to be encouraging.
- JYL's premium segments are growing.
- The company remains open to inorganic growth opportunities.
- New product launches are expected to accelerate growth, strengthen category relevance, and support long-term brand equity. The new product pipelines remains healthy.
- JYL remains focused on turning around the HI segment, with a focus on profitability. It has no plans to expand the coils category and will focus on liquid vaporizers, aerosol, and anti-mosquito rackets.
- The share of digital ad spends in overall ad spends has increased over the years.
- In 2QFY26, JYL has made significant investments in Margo, which, along with price hikes taken in December last year and high palm oil prices, has weighed on personal care EBIT margins. Over next couple of quarters, EBIT margins are expected to return to double digits.
- Rural markets contribute ~30-40% of revenues, with urban markets accounting for the remaining.
- The company continues to strengthen its distribution network, increasing direct reach to 1.3m outlets.

### **Costs and margins**

- Gross margin for the quarter was 48.1%, down 210bp YoY, mainly due to input cost pressure, price reduction, and consumer offers in select categories.
- RM prices remained stable sequentially.
- EBITDA margin is expected to be in the range of 16-17% in 2HFY26.

### Segmental details

### **Fabric care**

- The Fabric Care portfolio delivered a steady performance, with 6.1% growth for the quarter. The liquid detergent range continued to scale rapidly, with revenue more than doubling YoY, driven by strong growth across the portfolio.
- Detergent powders and bars maintained their momentum during the period.



- New launches made in the past few months have been well received and are delivering sales in line with the company's expectations.
- The company launched Dr. Wool, expanding its fabric care portfolio into a premium niche and strengthening its presence in specialized garment care.

### Dish wash

- The Dishwash portfolio reported a 3.8% decline in value terms for the quarter, primarily due to MRP reductions and grammage offers on bars. However, volumes remained healthy, with 3.4% volume growth during the quarter.
- Within the segment, liquids outperformed bars, supported by continued consumer adoption and strong brand equity.

### **Household Insecticides**

- The HI segment declined 8.9% for the quarter as the category continued to face near-term headwinds.
- The company remains focused on improving profitability over the next few quarters.
- Recently launched Maxo Aerosols and Anti-Mosquito Racquets are gaining encouraging traction.
- The medium-term objective remains to reduce losses and drive a structured turnaround of the category.

### **Personal Care**

- The Personal Care segment declined 4.3% for the quarter, largely impacted by the temporary disruption caused by the GST transition in September.
- JYL expects the segment to normalize and return to growth in 2HFY26.



# **Key exhibits**

Exhibit 1: Consolidated quarterly performance

Exhibit 1: Consolidated quar	rterly perfo	rmance								
Sales (INR m)	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26
Fabric Care	2,966	3,166	2,948	2,811	3,228	3,168	3,221	2,869	3,328	3,355
Dishwashing	2,315	2,507	2,361	2,183	2,480	2,540	2,446	2,252	2,482	2,444
Household Insecticides	494	450	457	722	503	451	344	687	455	411
Personal Care	841	896	723	618	932	856	697	564	939	819
Other Products	256	304	286	266	274	323	336	299	309	332
Total	6,871	7,323	6,775	6,600	7,418	7,338	7,045	6,670	7,512	7,361
Sales salience (%)										
Fabric Care	43	43	44	43	44	43	46	43	44	46
Dishwashing	34	34	35	33	33	35	35	34	33	33
Household Insecticides	7	6	7	11	7	6	5	10	6	6
Personal Care	12	12	11	9	13	12	10	8	13	11
Other Products	4	4	4	4	4	4	5	4	4	5
Total	100	100	100	100	100	100	100	100	100	100
Sales growth (%)										
Fabric Care	18	11	12	10	9	0	9	2	3	6
Dishwashing	11	10	7	6	7	1	4	3	0	(4)
Household Insecticides	10	3	5	(10)	2	0	(25)	(5)	(10)	(9)
Personal Care	21	22	22	18	11	(4)	(4)	(9)	1	(4)
Other Products	14	7	13	16	7	6	17	12	12	3
Total	15	11	11	7	8	0	4	1	1	0
EBIT (INR m)										
Fabric Care	656	828	744	647	802	789	716	642	676	737
Dishwashing	463	523	425	393	495	484	447	408	502	422
Household Insecticides	(94)	(79)	(93)	(75)	(54)	(43)	(102)	(48)	(48)	(40)
Personal Care	153	98	93	52	103	116	75	60	111	22
Other Products	5	1	15	(3)	(5)	24	5	11	6	3
Total	1,184	1,370	1,183	1,014	1,341	1,371	1,140	1,072	1,246	1,143
EBIT salience (%)										
Fabric Care	55	60	63	64	60	58	63	60	54	64
Dishwashing	39	38	36	39	37	35	39	38	40	37
Household Insecticides	(8)	(6)	(8)	(7)	(4)	(3)	(9)	(4)	(4)	(3)
Personal Care	13	7	8	5	8	8	7	6	9	2
Other Products	0	0	1	(0)	(0)	2	0	1	0	0
Total	100	100	100	100	100	100	100	100	100	100
EBIT margin (%)										
Fabric Care	22.1	26.1	25.2	23.0	24.9	24.9	22.2	22.4	20.3	22.0
Dishwashing	20.0	20.9	18.0	18.0	20.0	19.1	18.3	18.1	20.2	17.3
Household Insecticides	(19.0)	(17.6)	(20.4)	(10.4)	(10.8)	(9.5)	(29.7)	(7.0)	(10.6)	(9.7)
Personal Care	18.2	10.9	12.9	8.5	11.0	13.6	10.7	10.6	11.8	2.7
Other Products	1.9	0.2	5.3	(1.1)	(1.6)	7.5	1.5	3.7	1.8	0.9
Total	17.2	18.7	17.5	15.4	18.1	18.7	16.2	16.1	16.6	15.5

Source: Company, MOFSL




### Exhibit 2: Volume growth was ~3% in 2QFY26

### ■ Volume growth (%) 11 10 9 8 3 2 1 2QFY26 2QFY24 3QFY24 4QFY24 **2QFY25** 1QFY26 4QFY23 1QFY25 LQFY24


Source: Company, MOFSL

**Exhibit 3: Net sales remained flat YoY** 




Source: Company, MOFSL

Exhibit 4: Gross margin contracted 210bp YoY to 48.1%




Source: Company, MOFSL

Exhibit 5: EBITDA margin contracted 280bp YoY to 16.1%




Source: Company, MOFSL

Exhibit 6: EBITDA declined ~15% YoY in 2QFY26



Source: Company, MOFSL

Exhibit 7: APAT declined 16% YoY in 2QFY26



Source: Company, MOFSL


### Valuation and view


- We cut our EPS estimates by 2%-3% each for FY26E-28E.
- We believe that while 2HFY26 will be better than 1HFY26 for most FMCG names, elevated competitive intensity could limit JYL's growth in the near term. Market share gains, the success of new launches, a recovery in personal care, and the turnaround of the HI portfolio will be crucial for JYL's earnings growth. JYL's margin expansion beyond ~18% is also constrained by its focus on the mass and rural segments. Therefore, we believe its growth potential is adequately priced in at the current valuation. We reiterate our Neutral rating on the stock with a TP of INR350 (premised on 30x Sep'27E P/E).



Exhibit 8: We cut our EPS estimate by 2-3% each over FY26-28

		New			Old		Change (%)		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
Sales	29,912	32,325	35,047	30,121	32,550	35,292	-0.7%	-0.7%	-0.7%
EBITDA	4,964	5,587	6,183	5,212	5,805	6,433	-4.8%	-3.7%	-3.9%
PAT	3,796	4,288	4,762	3,921	4,384	4,876	-3.2%	-2.2%	-2.3%





Source: Company, MOFSL Source: Company, MOFSL



# **Financials and valuations**

Consolidated - Income Statemer										(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	18,136	17,112	19,091	21,965	24,860	27,569	28,470	29,912	32,325	35,047
Change (%)	8.4	-5.6	11.6	15.1	13.2	10.9	3.3	5.1	8.1	8.4
Cost of Materials Consumed	9,707	9,009	10,104	12,830	14,349	14,038	14,195	14,807	15,904	17,243
As a percentage of Sales	53.5	52.6	52.9	58.4	57.7	50.9	49.9	49.5	49.2	49.2
Gross Profit	8,429	8,103	8,987	9,135	10,511	13,531	14,275	15,106	16,421	17,804
Margin (%)	46.5	47.4	47.1	41.6	42.3	49.1	50.1	50.5	50.8	50.8
Personnel Expenses	2,076	2,193	2,325	2,475	2,644	3,005	3,258	3,320	3,588	3,890
As a percentage of Sales	11.4	12.8	12.2	11.3	10.6	10.9	11.4	11.1	11.1	11.1
Other Expenses	3,542	3,398	3,517	4,178	4,709	5,728	6,021	6,822	7,245	7,730
% of Sales	19.5	19.9	18.4	19.0	18.9	20.8	21.1	22.8	22.4	22.1
Total Expenditure	15,325	14,601	15,946	19,483	21,702	22,771	23,474	24,949	26,737	28,864
As a percentage of Sales	84.5	85.3	83.5	88.7	87.3	82.6	82.5	83.4	82.7	82.4
EBITDA	2,811	2,511	3,145	2,482	3,159	4,798	4,996	4,964	5,587	6,183
Margin (%)	15.5	14.7	16.5	11.3	12.7	17.4	17.5	16.6	17.3	17.6
Depreciation	306	529	556	582	501	500	561	601	643	688
EBIT	2,505	1,982	2,589	1,901	2,657	4,298	4,435	4,363	4,945	5,496
Int. and Finance Charges	352	329	192	118	131	47	59	62	65	69
Other Income	278	203	185	187	395	447	556	695	764	841
PBT bef. EO Exp.	2,430	1,856	2,581	1,969	2,922	4,698	4,931	4,996	5,644	6,268
EO Items	0	-38	-235	0	70	90	-43	0	0	0
PBT after EO Exp.	2,430	1,818	2,346	1,969	2,992	4,788	4,888	4,996	5,644	6,268
Current Tax	454	189	440	378	595	1,095	1,184	1,200	1,355	1,505
Tax Rate (%)	18.7	10.4	18.7	19.2	19.9	22.9	24.2	24.0	24.0	24.0
Reported PAT	2,051	1,706	1,994	1,620	2,397	3,695	3,704	3,796	4,288	4,762
Adjusted PAT	1,976	1,667	2,142	1,591	2,327	3,603	3,747	3,796	4,288	4,762
Change (%)	10.5	-15.6	28.5	-25.7	46.2	54.8	4.0	1.3	13.0	11.1
Margin (%)	10.9	9.7	11.2	7.2	9.4	13.1	13.2	12.7	13.3	13.6
Consolidated - Balance Sheet										(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E	FY28E
Equity Share Capital	367	367	367	367	367	367	367	367	367	367
Total Reserves	12,898	11,919	13,918	14,068	15,123	17,716	20,128	20,640	22,529	24,891
Net Worth	13,265	12,286	14,286	14,435	15,490	18,083	20,495	21,007	22,896	25,259
Minority Interest	-215	-291	-379	-407	21	19	0	0	0	0
Deferred Liabilities	-928	-1,027	-962	-907	-845	-594	-273	-273	-273	-273
Total Loans	2,809	2,830	1,169	1,265	0	1,062	400	0	0	0
Capital Employed	14,932	13,798	14,114	14,387	14,665	18,570	20,622	20,733	22,622	24,985
Gross Block	12,046	13,050	13,556	13,764	14,125	13,715	13,314	13,514	13,714	13,914
Less: Accum. Deprn.	1,040	1,558	2,089	2,546	2,962	2,462	1,901	2,502	3,144	3,832
Net Fixed Assets	11,006	11,492	11,467	11,218	11,163	11,253	11,413	11,013	10,570	10,083
Capital WIP	143	245	101	76	155	134	224	123	123	123
Total Investments	1,044	0	0	0	0	1,915	4,565	4,565	4,565	4,565
Curr. Assets, Loans&Adv.	6,301	5,598	7,029	8,027	8,454	10,108	9,550	10,914	14,032	17,826
Inventory	1,974	2,251	2,786	2,972	3,019	2,835	3,281	4,188	4,525	4,907
Account Receivables	1,534	1,224	944	1,431	1,378	2,014	2,744	1,496	1,616	1,752
Cash and Bank Balance	964	289	1,938	2,112	2,835	1,661	1,424	2,416	4,848	7,869
Loans and Advances & Others	1,830	1,834	1,361	1,512	1,222	3,599	2,101	2,815	3,042	3,298
Curr. Liability & Prov.	3,563	3,537	4,483	4,933	5,107	4,840	5,130	5,881	6,668	7,611
Account Payables										
Other Current Liabilities	2,134 715	1,450 1,299	2,143	2,364	2,143	2,761	2,903	2,991	3,232	3,505
			1,520	1,767	2,037	1,756	1,474	1,843	2,304	2,880
Provisions	715	788	820	802	927	324	753	1,047	1,131	1,227
Net Current Assets	2,738	2,061	2,546	3,093	3,347	5,268	4,419	5,033	7,365	10,215
Appl. of Funds	14,932	13,798	14,114	14,387	14,665	18,570	20,622	20,734	22,622	24,985

E: MOFSL Estimates



E: MOFSL Estimates

**Ratios** 

# **Financials and valuations**

Natios										
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E	FY27E	FY28E
Basic (INR)										
EPS	5.4	4.5	5.8	4.3	6.3	9.8	10.2	10.3	11.7	13.0
Cash EPS	6.2	6.0	7.3	5.9	7.7	11.2	11.7	12.0	13.4	14.8
BV/Share	36.1	33.5	38.9	39.3	42.2	49.2	55.8	57.2	62.4	68.8
DPS	6.0	0.0	4.0	2.5	3.0	3.5	3.5	5.4	5.4	5.4
Payout (%)	134	0	83	70	57	43	42	63	56	50
Valuation (x)										
P/E	57.6	68.3	53.2	71.5	48.9	31.6	30.4	30.0	26.5	23.9
Cash P/E	49.9	51.8	42.2	52.4	40.3	27.7	26.4	25.9	23.1	20.9
P/BV	8.6	9.3	8.0	7.9	7.3	6.3	5.6	5.4	5.0	4.5
EV/Sales	6.3	6.8	5.9	5.1	4.5	4.0	3.8	3.6	3.2	2.9
EV/EBITDA	40.8	46.3	35.9	45.5	35.1	23.2	21.7	21.5	18.7	16.4
Dividend Yield (%)	1.9	0.0	1.3	0.8	1.0	1.1	1.1	1.7	1.7	1.7
FCF per share	7.2	3.5	10.3	4.9	8.6	2.7	13.3	11.0	11.3	12.7
Return Ratios (%)										
RoE	16.0	13.0	16.1	11.1	15.6	21.5	19.4	18.3	19.5	19.8
RoCE	13.7	12.6	14.7	10.8	15.7	21.1	18.9	18.3	19.8	20.0
RoIC	15.7	13.6	16.6	12.7	17.8	25.0	23.0	23.6	28.1	32.7
<b>Working Capital Ratios</b>										
Asset Turnover (x)	1.2	1.2	1.4	1.5	1.7	1.5	1.4	1.4	1.4	1.4
Inventory (Days)	39.7	48.0	53.3	49.4	44.3	37.5	42.1	51.1	51.1	51.1
Debtor (Days)	30.9	26.1	18.0	23.8	20.2	26.7	35.2	18.3	18.3	18.3
Creditor (Days)	80.2	58.7	77.4	67.3	54.5	71.8	74.6	73.7	74.2	74.2
Working Cap. Turnover (Days)	35.7	37.8	11.6	16.3	7.5	47.8	38.4	31.9	28.4	24.4
Leverage Ratio (x)										
Current Ratio	1.8	1.6	1.6	1.6	1.7	2.1	1.9	1.9	2.1	2.3
Interest Cover Ratio	7	6	13	16	20	91	75	70	76	80
Debt/Equity	0.2	0.2	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0
Consolidated Cook Flour State										(INID)
Consolidated - Cash Flow State		EV20	EV24	EV22	EV22	EV24	EVac	EVACE		(INR m)
Y/E March OP/(Loss) before Tax	<b>FY19E</b> 2,430	<b>FY20</b> 1,815	<b>FY21</b> 2,346	<b>FY22</b> 1,969	<b>FY23</b> 2,992	<b>FY24</b> 4,698	<b>FY25</b> 4,931	<b>FY26E</b> 4,996	<b>FY27E</b> 5,644	FY28E
Depreciation	306	529	556	582	501	500	561	601	643	6,268 688
Interest & Finance Charges	314	304	161	82	54	47	59	62	65	69
Other income	-25	-21	232	-36	-197	-507	-395	-695	-764	-841
Direct Taxes Paid	-418	-386	-327	-313	-567	-1,095	-1,184	-1,200	-1,355	-1,505
(Inc)/Dec in WC	409	-527	1,055	-259	502	-3,095	612	378	101	170
CF from Operations	3,016	1,715	4,022	2,025	3,286	547	4,585	4,142	4,333	4,848
CF from Operating incl EO	3,016	1,715	4,022	2,025	3,286	547	4,585	4,142	4,333	4,848
(inc)/dec in FA	-383	-415	-257	-214	-122	432	310	-99	-200	-200
(Pur)/Sale of Investments	112	1,061	0	0	0	-1,915	-2,650	0	0	0
Others	37	4	45	29	65	303	-206	-190	764	841
CF from Investments	-234	650	-212	-185	-57	-1,181	-2,545	-289	564	641
Issue of Shares	4	0	0	0	0	0	0	0	0	0
(Inc)/Dec in Debt	-610	41	-1,669	100	-1,250	1,062	-662	-400	0	0
Interest Paid	-342	-212	-281	-74	-104	-47	-59	-62	-65	-69
Dividend Paid	-182	-2,656	0	-1,469	-918	-1,555	-1,555	-2,399	-2,399	-2,399
Others	-2,055	-211	-212	-224	-235	0	0	0	0	0
CF from Fin. Activity	-3,185	-3,039	-2,161	-1,667	-2,507	-540	-2,277	-2,861	-2,465	-2,468
Inc/Dec of Cash	-403	-674	1,649	174	723	-1,174	-237	992	2,433	3,021
Opening Balance	1,367	964	289	1,938	2,112	2,835	1,661	1,424	2,416	4,848
Closing Balance	964	289	1,938	2,112	2,835	1,661	1,424	2,416	4,848	7,869
F. MOFCL Estimates										

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

12 November 2025 9



### NOTES



Explanation of Investment Rating							
Investment Rating	Expected return (over 12-month)						
BUY	>=15%						
SELL	<-10%						
NEUTRAL	< - 10 % to 15%						
UNDER REVIEW	Rating may undergo a change						
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation						

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <a href="https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx">https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx</a>

A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>, <a href="www.nseindia.com">www.bseindia.com</a>. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

### For U.S.

Motial Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

### **Specific Disclosures**

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
   MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
   Nature of Financial interest is holding equity shares or derivatives of the subject company
   Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
  - MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report:No
- 3. Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
  - MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
   MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- 5. Research Analyst has not served as an officer, director or employee of subject company(ies).
- 6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- 7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- 8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- 9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have: financial interest in the subject company



- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. **Analyst Certification** 

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Aganwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell

Chief and Cook Com		
Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent - CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.

12 12 November 2025